This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Brzozowski RS , Wuest WM
Twelve-membered macrolactones: privileged scaffolds for the development of new therapeutics
Chem Biol Drug Des. 2017 Feb;89(2) :169-191
PMID: 27153932 URL: https://www.ncbi.nlm.nih.gov/pubmed/27153932
AbstractNatural products commonly produced as secondary metabolites of various plants and micro-organisms represent a diverse chemical space of compounds. The diversity of natural products makes them an attractive target for interrogation by both chemists and biologists alike. Indeed, the study of 12-membered macrolactones has already led to the discovery of lead drug compounds and new biological targets, which has motivated the development of diverted total synthetic routes to libraries of analogs. This review explores the discovery, biological characterization, and synthesis of several 12-membered macrolactones, exploiting examples that underscore their importance in the drug discovery field. It is our hope that this review will motivate further interest in this class of natural products, a group of molecules that we think merit the classification of 'privileged scaffolds' within the medicinal chemistry community, to further investigate and develop novel compounds with promising bioactivity.
Notes1747-0285 Brzozowski, Richard S Wuest, William M Journal Article R01 DE025837/DE/NIDCR NIH HHS/ Review England Chem Biol Drug Des. 2017 Feb;89(2):169-191. doi: 10.1111/cbdd.12783.